TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TextFluenza: Using Technology To Promote Flu Vaccination In Underserved Maternal And Child Population
Brief Summary: The Advisory Committee on Immunization Practices (ACIP)recommends that the flu vaccine be administered annually to all children aged 6 months to 18 years as well as women who are pregnant during the influenza season. Nevertheless, targeting and mobilizing these populations has been difficult and influenza immunization rates nationwide remain low. Immunization reminder-recalls have been shown to be effective, but have had limited ability to rapidly identify and reach large target populations in a cost-effective manner. Evidence on how to optimally design these systems is not yet available and thus text message immunization alerts have not been widely implemented. The investigators propose to implement and evaluate tailored, targeted influenza text message reminders in urban pediatric and pregnant populations.


Options:
A: Arm Label: mhealth intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mhealth intervention | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mhealth intervention; Assigned to Arm(s): mhealth intervention
B: Arm Label: texting group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: text messages focused on smoking cessation and pregnancy | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: text messages focused on smoking cessation and pregnancy; Assigned to Arm(s): texting group
C: Arm Label: Text message vaccine reminders; Type: EXPERIMENTAL; Interventions: Other: Text Message, Other: automated call | Arm Label: automated phone call from clinic; Type: ACTIVE_COMPARATOR; Interventions: Other: automated call | Intervention Type: OTHER; Name: Text Message; Assigned to Arm(s): Text message vaccine reminders | Intervention Type: OTHER; Name: automated call; Assigned to Arm(s): Text message vaccine reminders, automated phone call from clinic
D: Arm Label: SMS Vaccine; Type: N/A; Interventions: Behavioral: SMS message reminding mothers to come for their scheduled vaccines | Arm Label: Usual care; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SMS message reminding mothers to come for their scheduled vaccines; Assigned to Arm(s): SMS Vaccine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome
Brief Summary: Primary Objective:

- To demonstrate that lixisenatide can reduce cardiovascular (CV) morbidity and mortality (composite endpoint of CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina) compared to placebo in type 2 diabetic participants who recently experienced an acute coronary syndrome (ACS) event.

Secondary Objectives:

To demonstrate that when compared to placebo, lixisenatide can reduce:

* composite endpoint of CV death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina, or hospitalization for heart failure.
* composite endpoint of CV death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina, hospitalization for heart failure, or coronary revascularization procedure.
* urinary albumin excretion (based on the urinary albumin/creatinine ratio).

To assess the safety and tolerability of lixisenatide.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Intensive Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive lifestyle; Assigned to Arm(s): Intensive Lifestyle | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Saxagliptin; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Lixisenatide; Type: EXPERIMENTAL; Interventions: Drug: Lixisenatide (AVE0010) | Intervention Type: DRUG; Name: Lixisenatide (AVE0010); Assigned to Arm(s): Lixisenatide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Liraglutid; Type: ACTIVE_COMPARATOR; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Activity Benefits After Breast Cancer: Exploring Cytokine Mechanisms
Brief Summary: The purpose of the study is to examine the benefits of physical activity for breast cancer survivors related to muscle strength, tiredness, and sleep quality. Also, the study will determine the potential role of inflammation in these benefits.


Options:
A: Arm Label: Exercise Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity counseling | Arm Label: Contact Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity counseling; Assigned to Arm(s): Exercise Counseling
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise intervention; Type: EXPERIMENTAL; Interventions: Behavioral: 3 month physical activity intervention | Intervention Type: BEHAVIORAL; Name: 3 month physical activity intervention; Assigned to Arm(s): Exercise intervention
C: Arm Label: Lifestyle counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: behavioral dietary intervention, Other: counseling intervention, Other: educational intervention, Other: preventative dietary intervention, Procedure: quality-of-life assessment | Arm Label: Without Counseling; Type: ACTIVE_COMPARATOR; Interventions: Procedure: quality-of-life assessment | Intervention Type: BEHAVIORAL; Name: behavioral dietary intervention; Assigned to Arm(s): Lifestyle counseling | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): Lifestyle counseling | Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): Lifestyle counseling | Intervention Type: OTHER; Name: preventative dietary intervention; Assigned to Arm(s): Lifestyle counseling | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Lifestyle counseling, Without Counseling
D: Arm Label: Rehabilitation Group; Type: EXPERIMENTAL; Interventions: Behavioral: Pulmonary Rehabilitation Program | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pulmonary Rehabilitation Program; Assigned to Arm(s): Rehabilitation Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Physical Activity Benefits After Breast Cancer: Exploring Cytokine Mechanisms
Brief Summary: The purpose of the study is to examine the benefits of physical activity for breast cancer survivors related to muscle strength, tiredness, and sleep quality. Also, the study will determine the potential role of inflammation in these benefits.


Options:
A: Arm Label: Telerehabilitation group; Type: EXPERIMENTAL; Interventions: Behavioral: Telerehabilitation group | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Telerehabilitation group; Assigned to Arm(s): Telerehabilitation group
B: Arm Label: Physical activity intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): Physical activity intervention
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise intervention; Type: EXPERIMENTAL; Interventions: Behavioral: 3 month physical activity intervention | Intervention Type: BEHAVIORAL; Name: 3 month physical activity intervention; Assigned to Arm(s): Exercise intervention
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: CBT and relaxation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: CBT and physical activity | Arm Label: 4; Type: NO_INTERVENTION; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: CBT and relaxation; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Physical activity; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: CBT and physical activity; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): 4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Control Trial of Misoprostol Versus Placebo for Cervical Priming in Intrauterine Device Insertion for Nulliparous Women
Brief Summary: Because of misoprostol's known ability to cause cervical dilation, some family planning providers give their patients a dose of this drug prior to insertion. The goal of this study is to evaluate whether misoprostol prior to IUD insertion in nulliparous women eases insertion and decreases pain.


Options:
A: Arm Label: misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: LNG-IUS; Type: N/A; Interventions: Other: Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up. | Arm Label: Cu-IUD; Type: N/A; Interventions: Other: Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up. | Intervention Type: OTHER; Name: Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.; Assigned to Arm(s): Cu-IUD, LNG-IUS
D: Arm Label: saline spray application; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: lidocaine spray application; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine Spray | Intervention Type: DRUG; Name: Lidocaine Spray; Assigned to Arm(s): lidocaine spray application | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): saline spray application

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Spironolactone and Vitamin E Versus Vitamin E on Serum Adipocytokines Levels in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease-A Phase II Study
Brief Summary: The primary aim of the study is the effect of spironolactone and vitamin E versus vitamin E on serum levels of adipokines 52 weeks post-treatment.


Options:
A: Arm Label: Vitamin E; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone/Vitamin E | Intervention Type: DRUG; Name: Spironolactone/Vitamin E; Assigned to Arm(s): Vitamin E
B: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: Liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Liraglutide-placebo | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: OTHER; Name: Liraglutide-placebo; Assigned to Arm(s): Placebo
C: Arm Label: 25 mg INT-747; Type: ACTIVE_COMPARATOR; Interventions: Drug: INT-747 | Arm Label: 50 mg INT-747; Type: ACTIVE_COMPARATOR; Interventions: Drug: INT-747 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: INT-747; Assigned to Arm(s): 25 mg INT-747, 50 mg INT-747 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Ezetimibe; Type: EXPERIMENTAL; Interventions: Drug: Ezetimibe | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ezetimibe | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Brief Summary: The present study is a randomized, blinded, placebo-controlled, two-Phase, sequential cohort, dose finding study to assess the safety and efficacy of eltrombopag in patients with solid tumors receiving gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin. Phase I of the study will examine safety and tolerability of various doses of eltrombopag to identify a dose and schedule of eltrombopag. Phase II will confirm that the chosen dose and schedule of eltrombopag from Phase I can deliver clinically meaningful benefit(s) to thrombocytopenic patients by improving platelet numbers.


Options:
A: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: SB497115 | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: SB497115; Assigned to Arm(s): Arm 1, Arm 2, Arm 3 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Arm
B: Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: eltrombopag | Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: eltrombopag | Intervention Type: DRUG; Name: eltrombopag; Assigned to Arm(s): Group A, Group B
C: Arm Label: Eltrombopag; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eltrombopag olamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Eltrombopag olamine; Assigned to Arm(s): Eltrombopag | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Part A: 300 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 700 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 1000 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: 1500 µg romiplostim; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim SC QW; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim SC Q2W; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: 750 µg romiplostim IV Q2W; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Intervention Type: DRUG; Name: Romiplostim; Assigned to Arm(s): Part A: 1000 µg romiplostim, Part A: 1500 µg romiplostim, Part A: 300 µg romiplostim, Part A: 700 µg romiplostim, Part B: 750 µg romiplostim IV Q2W, Part B: 750 µg romiplostim SC Q2W, Part B: 750 µg romiplostim SC QW

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Brief Summary: The present study is a randomized, blinded, placebo-controlled, two-Phase, sequential cohort, dose finding study to assess the safety and efficacy of eltrombopag in patients with solid tumors receiving gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin. Phase I of the study will examine safety and tolerability of various doses of eltrombopag to identify a dose and schedule of eltrombopag. Phase II will confirm that the chosen dose and schedule of eltrombopag from Phase I can deliver clinically meaningful benefit(s) to thrombocytopenic patients by improving platelet numbers.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Therapeutic platelet transfusion | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Prophylactic platelet transfusion | Intervention Type: BIOLOGICAL; Name: Prophylactic platelet transfusion; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Therapeutic platelet transfusion; Assigned to Arm(s): 1
B: Arm Label: Eltrombopag; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eltrombopag olamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Eltrombopag olamine; Assigned to Arm(s): Eltrombopag | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Eltrombopag | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Drug: Eltrombopag | Arm Label: Arm D; Type: EXPERIMENTAL; Interventions: Drug: Eltrombopag | Arm Label: Arm E; Type: EXPERIMENTAL; Interventions: Drug: Eltrombopag | Arm Label: Arm A; Type: OTHER; Interventions: Drug: Eltrombopag | Intervention Type: DRUG; Name: Eltrombopag; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Eltrombopag; Assigned to Arm(s): Arm B, Arm C, Arm D, Arm E
D: Arm Label: WAS patients receiving Promacta; Type: EXPERIMENTAL; Interventions: Drug: Promacta | Arm Label: WAS patients for blood drawing only; Type: EXPERIMENTAL; Interventions: Diagnostic Test: blood drawing in patients with WAS | Arm Label: healthy children for blood drawing only; Type: PLACEBO_COMPARATOR; Interventions: Diagnostic Test: blood drawing in healthy controls | Intervention Type: DRUG; Name: Promacta; Assigned to Arm(s): WAS patients receiving Promacta | Intervention Type: DIAGNOSTIC_TEST; Name: blood drawing in patients with WAS; Assigned to Arm(s): WAS patients for blood drawing only | Intervention Type: DIAGNOSTIC_TEST; Name: blood drawing in healthy controls; Assigned to Arm(s): healthy children for blood drawing only

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Double-dummy, Parallel-group Multicentre Study to Assess Efficacy and Safety of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Propionate/Salmeterol Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents
Brief Summary: The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily with fluticasone propionate/salmeterol administered twice daily in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 24-week period.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Drug: Symbicort pMDI + budesonide HFA pMDI | Intervention Type: DRUG; Name: budesonide/formoterol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Symbicort pMDI + budesonide HFA pMDI; Assigned to Arm(s): 2
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: tiotropium low dose | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: tiotropium high dose | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tiotropium high dose; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C | Intervention Type: DRUG; Name: tiotropium low dose; Assigned to Arm(s): A
C: Arm Label: Fluticasone furoate/Vilanterol (GW642444); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate/Vilanterol Inhalation Powder, Drug: Placebo (2) | Arm Label: Fluticasone propionate/salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/salmeterol Inhalation Powder, Drug: Placebo (1) | Intervention Type: DRUG; Name: Fluticasone furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444) | Intervention Type: DRUG; Name: Fluticasone propionate/salmeterol Inhalation Powder; Assigned to Arm(s): Fluticasone propionate/salmeterol | Intervention Type: DRUG; Name: Placebo (1); Assigned to Arm(s): Fluticasone propionate/salmeterol | Intervention Type: DRUG; Name: Placebo (2); Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444)
D: Arm Label: tiotropium 5mcg/day; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 5mcg/day | Arm Label: placebo; Type: EXPERIMENTAL; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tiotropium 5mcg/day; Assigned to Arm(s): tiotropium 5mcg/day | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice
Brief Summary: This is a phase 4, multicenter, randomized, non-therapeutic interventional trial in subjects with psoriasis looking for the prevalence of psoriatic arthritis. Subjects will be seen and evaluated by a dermatologist at visit 1 and by a rheumatologist at visit 2. A subset of subjects will then go on to visit 3 for imaging procedures (x-ray, MRI, and ultrasound).


Options:
A: Arm Label: Secukinumab (AIN457) 75 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 150 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Secukinumab (AIN457) 300 mg s.c.; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab (AIN457) | Arm Label: Placebo s.c.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Secukinumab (AIN457), Drug: Placebo | Intervention Type: DRUG; Name: Secukinumab (AIN457); Assigned to Arm(s): Placebo s.c., Secukinumab (AIN457) 150 mg s.c., Secukinumab (AIN457) 300 mg s.c., Secukinumab (AIN457) 75 mg s.c. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c.
B: Arm Label: Intensive management; Type: EXPERIMENTAL; Interventions: Drug: Intensive management or Tight control | Arm Label: Standard management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard management - Control group | Intervention Type: DRUG; Name: Intensive management or Tight control; Assigned to Arm(s): Intensive management | Intervention Type: DRUG; Name: Standard management - Control group; Assigned to Arm(s): Standard management
C: Arm Label: psoriatic arthritis (PsA) questionnaire; Type: NO_INTERVENTION; Interventions: Procedure: lab draws and imaging | Intervention Type: PROCEDURE; Name: lab draws and imaging; Assigned to Arm(s): psoriatic arthritis (PsA) questionnaire
D: Arm Label: Infliximab + methotrexate (IFX + MTX); Type: EXPERIMENTAL; Interventions: Drug: Infliximab + methotrexate (IFX + MTX) | Arm Label: Methotrexate (MTX); Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate (MTX) | Intervention Type: DRUG; Name: Infliximab + methotrexate (IFX + MTX); Assigned to Arm(s): Infliximab + methotrexate (IFX + MTX) | Intervention Type: DRUG; Name: Methotrexate (MTX); Assigned to Arm(s): Methotrexate (MTX)

Answer: C